Anti-TNF-α biotherapies: perspectives for evidence-based personalized medicine.
about
Assessing the Immunogenicity of BiopharmaceuticalsImmunogenicity of Anti-TNF-α Biotherapies: II. Clinical Relevance of Methods Used for Anti-Drug Antibody DetectionMechanistic Basis for Functional Promiscuity in the TNF and TNF Receptor Superfamilies: Structure of the LIGHT:DcR3 AssemblyImmunogenicity and PK/PD evaluation in biotherapeutic drug development: scientific considerations for bioanalytical methods and data analysis.Evaluation of the Cross-reactivity of Antidrug Antibodies to CT-P13 and Infliximab Reference Product (Remicade): An Analysis Using Immunoassays Tagged with Both Agents.Effect of Infliximab Dose Increase in Rheumatoid Arthritis at Different Trough Concentrations: A Cohort Study in Clinical Practice Conditions.Will bevacizumab biosimilars impact the value of systemic therapy in gynecologic cancers?Review article: immunogenicity of anti-TNF biologics in IBD - the role of patient, product and prescriber factors.A development that may evolve into a revolution in medicine: mRNA as the basis for novel, nucleotide-based vaccines and drugsBiological anti-TNF drugs: immunogenicity underlying treatment failure and adverse events.Optimizing Treatment with TNF Inhibitors in Inflammatory Bowel Disease by Monitoring Drug Levels and Antidrug Antibodies.Off-label use of tumour necrosis factor-alpha inhibitors and anakinra at an Australian tertiary hospital.Detection of adalimumab and anti-adalimumab antibodies in patients with rheumatoid arthritis: a comprehensive overview of methodology pitfalls and benefits.Mass Spectrometry Approaches for Identification and Quantitation of Therapeutic Monoclonal Antibodies in the Clinical Laboratory.Antibodies to infliximab and adalimumab in patients with rheumatoid arthritis in clinical remission: a cross-sectional study.Role for therapeutic drug monitoring during induction therapy with TNF antagonists in IBD: evolution in the definition and management of primary nonresponse.Biosimilars: Key regulatory considerations and similarity assessment tools.The Role of Rituximab in Chronic Lymphocytic Leukemia Treatment and the Potential Utility of Biosimilars.Letter: can addition of an immunomodulator really reverse antibody formation and loss of response in patients treated with adalimumab?Individualized Therapy Is a Long-Term Cost-Effective Method Compared to Dose Intensification in Crohn's Disease Patients Failing Infliximab.Outcomes After Primary Infliximab Treatment Failure in Inflammatory Bowel Disease.
P2860
Q26751485-B3140EC4-8BA8-459D-A56B-670712B44A55Q26865822-2CCC8510-5D82-4197-BFD0-04CF126B7EEBQ27684921-3ED01619-3201-4FED-AA58-178BFFD4A50FQ30716340-3B22F004-EF28-49A4-950B-3BC162ACDB4AQ33726030-AE7D41B7-4A5C-4FE6-94B6-4D109066C4A8Q36133890-52325AB1-4A4C-496D-BD70-7120C5DE85CAQ37715530-D09709B7-F43B-4852-9B84-8DA2F323EFDAQ38151885-78D7AADA-A33A-4BEE-94B5-1DA728B181BDQ38206520-2F7158B9-3220-437D-84A3-FEECDB72AEC7Q38643965-18DAD1BB-B3AF-48DE-A855-97A5D58C5169Q38822920-CD0E5D7F-CF55-4EE5-9FFD-6CEB69805DEBQ38826765-E804418E-BD57-4F77-A5A8-2088066DDB1BQ38898145-89AE0D8E-3352-41D2-8ABF-61D141AA6B29Q39169309-26225A08-8376-4612-9EBB-E5573F518B54Q41248107-6BD3E363-7C44-43C4-8BA4-6098C96005E6Q43988900-356B3AAB-C53E-4A95-BCFE-B6DD3A82CC56Q46729332-F49E0F9F-3A16-4DD3-A462-3DBD9905112AQ47796704-B80B8093-1BB2-43C5-96BC-44D3CE6C6E0EQ48285639-D4A96B7C-BB9D-44A1-AA9C-17A24F73493CQ50960517-3691DC59-C227-441F-B75B-E20D4D454739Q53331247-3072B5C4-3F2D-44CA-A3C3-42F984ADED58
P2860
Anti-TNF-α biotherapies: perspectives for evidence-based personalized medicine.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Anti-TNF-α biotherapies: perspectives for evidence-based personalized medicine.
@en
type
label
Anti-TNF-α biotherapies: perspectives for evidence-based personalized medicine.
@en
prefLabel
Anti-TNF-α biotherapies: perspectives for evidence-based personalized medicine.
@en
P2860
P356
P1433
P1476
Anti-TNF-α biotherapies: perspectives for evidence-based personalized medicine.
@en
P2093
Klaus Bendtzen
P2860
P304
P356
10.2217/IMT.12.114
P577
2012-11-01T00:00:00Z